Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$139.93 USD

139.93
30,973

-0.01 (-0.01%)

Updated Oct 9, 2024 10:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

by Zacks Equity Research

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse

by Zacks Equity Research

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

Masimo (MASI) Strengthens Global Footprint With New Launch

by Zacks Equity Research

Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.

Masimo (MASI) Up 6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study

by Zacks Equity Research

Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.

Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study

by Zacks Equity Research

Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.

Here's Why Momentum in Masimo (MASI) Should Keep going

by Zacks Equity Research

Masimo (MASI) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Masimo's (MASI) Q2 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.

Masimo (MASI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 2.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Boosts Its Product Suite With Latest Release

by Zacks Equity Research

Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.

Debanjana Dey headshot

MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on

by Debanjana Dey

Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.

Masimo (MASI) Reports Study Findings Backing the SedLine

by Zacks Equity Research

Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.

Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod

by Zacks Equity Research

Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.

Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study

by Zacks Equity Research

Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.

Masimo (MASI) Down 4.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome

by Zacks Equity Research

Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.

Masimo (MASI) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 2.27% and 0.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold Masimo (MASI) in Your Portfolio

by Zacks Equity Research

Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.

Debanjana Dey headshot

4 Critical Care Device Stocks to Deflect the COVID-19 Curveball

by Debanjana Dey

Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.

Ecolab (ECL) Unveils Its Enhanced Smart Water Navigator

by Zacks Equity Research

Ecolab's (ECL) smart tool is expected to bridge the widening gap between freshwater supply and demand via efficient water management.

Masimo (MASI) Down 10.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Study Favors Masimo's (MASI) Pulse Oximetry to Screen CCHD

by Zacks Equity Research

The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.